Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Gains from Investment Securities of $84000.0 for Q1 2026, down 83.91% quarter-over-quarter from $522000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Gains from Investment Securities for 7 years, with the latest figure at $84000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $84000.0; the trailing twelve-month figure through Mar 2026 stood at $956000.0 (down 18.43% YoY), and the FY2025 full-year result was $200000.0, down 76.91% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $84000.0, down from $522000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $6.8 million in Q1 2023, with the low at -$31000.0 in Q4 2023.
- Historically, Gains from Investment Securities has averaged $2.4 million across 5 years, with a median of $847000.0 in 2024.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities sank 101.51% — and 2024, when it jumped 3880.65%.
- Barinthus Biotherapeutics' Gains from Investment Securities stood at $2.1 million in 2022, then slumped by 101.51% to -$31000.0 in 2023, then jumped by 3880.65% to $1.2 million in 2024, then slumped by 55.46% to $522000.0 in 2025, then slumped by 83.91% to $84000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $84000.0 (Q1 2026), $522000.0 (Q4 2025), and $50000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Barinthus Biotherapeutics | 27.78 Mn | -39.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 522,000.00 |
| Dec 31, 2025 | 522,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 60,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Dec 31, 2023 | -31,000.00 |
| Dec 31, 2023 | -31,000.00 |
| Sep 30, 2023 | 6.39 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 6.78 Mn |
| Mar 31, 2023 | 6.81 Mn |
| Mar 31, 2023 | 6.81 Mn |